Latest Breaking News On - Schedulei european union - Page 7 : comparemela.com

Pharmadrug Inc : PharmaDrug Initiates Preclinical Study of Cepharanthine to Both Broaden Its Cancer Scope and to Streamline Its Strategy for Esophageal Cancer

Pharmadrug Inc.: PharmaDrug Initiates Preclinical Study of Cepharanthine to Both Broaden Its Cancer Scope and to Streamline Its Strategy for Esophageal Cancer PharmaDrug or the Company ), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a service agreement with a respected contract research organization (CRO) with deep expertise in preclinical oncology model development and drug testing, to evaluate the Company s patented enteric-coated formulation of Cepharanthine ( PD-001 ) in a broad panel of human cancers. We are focused on advancing the clinical development of our novel Cepharanthine formulation that not only has significant potential for infectious diseases, but also in select rare forms of cancer with high unmet medical needs, said Daniel Cohen, CEO of PharmaDrug

United statesLiy pleiotropicWangy cepharanthineDaniel cohenNemesb hemorheologicalClin hemorheol microcircNewsfile corpSchedulei european unionPharmadrug incOrphan drug designationEnteric coated cepharanthinePharmadrug production gmbhSuper smartSairiyo therapeuticsRegarding forward looking informationIntj mol

Pharmadrug Inc : PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

Pharmadrug Inc.: PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation PharmaDrug or the Company ), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation ( ODD ) to dimethyltryptamine ( DMT ) for prevention of ischemia-reperfusion injury ( IRI ) in patients undergoing solid organ transplantation, which includes the liver, kidney, heart and lung, to the Company s wholly-owned subsidiary Sairiyo Therapeutics Inc. The FDA ODD granted is broader than the Company s original application for kidney transplantation, recognizing the pernicious consequences of IRI in all solid organ transplantation.

United statesNemesb hemorheologicalClin hemorheol microcircDaniel cohenSairiyo therapeutics incNewsfile corpSchedulei european unionPharmadrug incDrug administrationTransplantation networkOrphan drug designationSairiyo therapeuticsInvestigational new drugOrphan drug actDrug applicationPharmadrug production gmbh

Pharmadrug Inc : PharmaDrug Advances Product and Clinical Development of Cepharanthine to Treat Rare Cancers and Infectious Diseases

Pharmadrug Inc.: PharmaDrug Advances Product and Clinical Development of Cepharanthine to Treat Rare Cancers and Infectious Diseases PharmaDrug or the Company ), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into an agreement with Southwest Research Institute® ( SwRI® ), to initiate non-clinical and clinical manufacturing of Cepharanthine for the Company s rare cancer and infectious diseases programs. In connection with PharmaDrug s recent acquisition of Sairiyo Therapeutics Inc., the Company has secured an exclusive license from SwRI to develop and commercialize a novel oral formulation of Cepharanthine for all fields of use as well as exclusive rights to U.S. Patent: 10,576,077, titled Pharmaceutical Salt forms of Cepharanthine and Tetrandrine . Formalization o

United statesJapan generalBaden wübergDaniel cohenBaillyc cepharanthineSairiyo therapeutics incNewsfile corpSchedulei european unionResearch institutePharmadrug incHealth canadaSouthwest research instituteDrug designationMiddle eastPharmadrug production gmbhSuper smart

PharmaDrug Advances Product and Clinical Development of Cepharanthine to Treat Rare Cancers and Infectious Diseases

PharmaDrug Advances Product and Clinical Development of Cepharanthine to Treat Rare Cancers and Infectious Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJapan generalBaden wübergDaniel cohenBaillyc cepharanthineSairiyo therapeutics incNewsfile corpSchedulei european unionResearch institutePharmadrug incHealth canadaSouthwest research instituteDrug designationMiddle eastPharmadrug production gmbhSuper smart

Pharmadrug Inc : Pharmadrug Initiates DMT Research Activities via Collaboration with the University of Michigan for Foundational DMT Research Study

Pharmadrug Inc : Pharmadrug Initiates DMT Research Activities via Collaboration with the University of Michigan for Foundational DMT Research Study
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJimo borjiginDaniel cohenJohns hopkins universitySchedulei european unionDepartment of neurologyPharmadrug incUniversity of michiganNewsfile corpUniversity of michigan medical schoolDepartment of molecularPrincipal investigatorConsciousness scienceMichigan medical schoolAssociate professorIntegrative physiology